Patients researching KISQALI cost are often looking for ways to better manage out-of-pocket expenses. ProviderX helps eligible patients coordinate access to KISQALI (ribociclib) through licensed pharmacies in Tijuana, Mexico, using a structured cross-border prescription program.
Based on recent cross-border quotes, many patients report meaningful KISQALI cost savings compared to typical U.S. cash pharmacy prices. Savings vary depending on prescription details, dosage strength, availability, and pharmacy partner.
Savings are estimates only. Final costs depend on prescription details, pharmacy, and availability. ProviderX does not prescribe medications, operate a pharmacy, or ship medications into the United States.
*Example medication packaging from licensed providers in Tijuana.
KISQALI is a specialty prescription medication, which often requires additional coordination compared to standard prescriptions. Below is a clear, step-by-step overview of how access is coordinated through ProviderX.
Step 1 — Send us your prescription securely
Upload your valid U.S. prescription for KISQALI through our HIPAA-secure form. We only work with prescriptions issued by licensed U.S. healthcare providers.
Step 2 — We coordinate your visit to Tijuana
Once eligibility is confirmed, our team coordinates the logistics required for your visit to Tijuana and prepares the medication pickup with licensed pharmacy partners.
Step 3 — Visit licensed pharmacies in person
You will visit licensed pharmacies in Tijuana where KISQALI is prepared and made available in accordance with international regulatory standards.
Step 4 — Pick up your medication and return home
Pick up your medication in person and return home the same day, with guidance and coordination support throughout the process.
What KISQALI is
KISQALI (ribociclib) is a prescription medication classified as a cyclin-dependent kinase (CDK) 4/6 inhibitor. It is manufactured by Novartis and is available only with a valid prescription.
Approved medical uses (factual)
According to official prescribing information, KISQALI is approved for use in patients with hormone receptor–positive (HR+), human epidermal growth factor receptor 2–negative (HER2−) breast cancer. It is indicated for use in combination with endocrine therapy in specific treatment settings, including certain early and advanced/metastatic disease contexts, as defined in the approved labeling.
Important medical notice
This information is provided for educational purposes only. ProviderX does not provide medical care, prescribe medications, or offer treatment recommendations. Decisions regarding KISQALI should be made by a licensed healthcare provider familiar with the patient’s medical history.
Fermentum tincidunt laoreet donec
Fermentum tincidunt laoreet donec
Nisl adipiscing leo id magna egestas eget dapibus enim et. Massa non scelerisque porttitor.
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
R
S
T
V
X
